ProMIS Neurosciences Total Current Assets Over Time
| PMN Stock | USD 0.94 0.02 2.08% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ProMIS Neurosciences Performance and ProMIS Neurosciences Correlation. ProMIS |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProMIS Neurosciences. If investors know ProMIS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProMIS Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.04 | Revenue Per Share 0.001 | Return On Assets (4.81) | Return On Equity (10.99) |
The market value of ProMIS Neurosciences is measured differently than its book value, which is the value of ProMIS that is recorded on the company's balance sheet. Investors also form their own opinion of ProMIS Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is ProMIS Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProMIS Neurosciences' market value can be influenced by many factors that don't directly affect ProMIS Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProMIS Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProMIS Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Current Assets Analysis
Compare ProMIS Neurosciences and related stocks such as biOasis Technologies, Zenith Capital Corp, and Hemogenyx Pharmaceuticals Total Current Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FENC | 435.9 K | 5.4 M | 2.4 M | 1.8 M | 2.4 M | 1 M | 4 M | 28.4 M | 22.9 M | 13.9 M | 31.4 M | 22.4 M | 26.7 M | 26.9 M | 28.2 M |
| GANX | 494.6 K | 494.6 K | 494.6 K | 494.6 K | 494.6 K | 494.6 K | 494.6 K | 494.6 K | 494.6 K | 429.5 K | 9 M | 37.7 M | 21.1 M | 17.8 M | 15.9 M |
| BIVI | 505.7 K | 505.7 K | 505.7 K | 332.9 K | 269.5 K | 130.7 K | 5.1 K | 45.8 K | 674.1 K | 413 K | 4.6 M | 18.8 M | 34 M | 24 M | 25.3 M |
| INAB | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 763 K | 18.1 M | 39 M | 22.2 M | 24.6 M | 20.1 M |
| NAMS | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 58.9 M | 448.1 M | 346.8 M | 237.3 M |
| CUE | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 15.1 M | 65.1 M | 40.6 M | 61 M | 87.5 M | 68.5 M | 77.2 M | 51.5 M | 57.8 M |
| NAMSW | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 58.9 M | 448.1 M | 346.8 M | 237.3 M |
| CNTA | 19.2 M | 19.2 M | 19.2 M | 19.2 M | 19.2 M | 19.2 M | 19.2 M | 19.2 M | 19.2 M | 19.2 M | 11.2 M | 595.1 M | 393.6 M | 315.1 M | 293.5 M |
| STRO | 49.7 M | 49.7 M | 49.7 M | 49.7 M | 49.7 M | 49.7 M | 49.7 M | 25.6 M | 209.9 M | 128.6 M | 378.2 M | 218.5 M | 309.5 M | 421.5 M | 239.5 M |
| OPT | 1 M | 18.8 M | 11.4 M | 9.4 M | 16.8 M | 12.4 M | 42.5 M | 33.2 M | 18.1 M | 49 M | 184 M | 87.1 M | 147.8 M | 188.2 M | 197.6 M |
| HLVX | 451 K | 451 K | 451 K | 451 K | 451 K | 451 K | 451 K | 451 K | 451 K | 451 K | 505 K | 124.7 M | 290.6 M | 310.7 M | 159.9 M |
| GLUE | 9.8 M | 9.8 M | 9.8 M | 9.8 M | 9.8 M | 9.8 M | 9.8 M | 9.8 M | 9.8 M | 9.8 M | 43.6 M | 348.7 M | 275.9 M | 236.2 M | 201.1 M |
| IVA | 16.2 M | 16.2 M | 16.2 M | 16.2 M | 21.5 M | 28.6 M | 41.2 M | 67.2 M | 71.6 M | 48.9 M | 133 M | 115.6 M | 106.4 M | 48.2 M | 69.8 M |
| CGEM | 12.7 K | 12.7 K | 12.7 K | 12.7 K | 6.3 K | 118 | 3.4 K | 34.2 M | 34.2 M | 100.1 M | 212.3 M | 296.6 M | 474.5 M | 480.2 M | 504.2 M |
| CMPX | 58.9 M | 58.9 M | 58.9 M | 58.9 M | 58.9 M | 58.9 M | 58.9 M | 58.9 M | 58.9 M | 26.2 M | 50.2 M | 147.1 M | 194.8 M | 153.9 M | 115.7 M |
ProMIS Neurosciences and related stocks such as biOasis Technologies, Zenith Capital Corp, and Hemogenyx Pharmaceuticals Total Current Assets description
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.My Equities
My Current Equities and Potential Positions
| ProMIS Neurosciences | PMN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Ontario; Canada |
| Exchange | NASDAQ Exchange |
USD 0.94
Check out ProMIS Neurosciences Performance and ProMIS Neurosciences Correlation. To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
ProMIS Neurosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.